Company news
Greenwich Lifesciences, Inc. (NASDAQ:GLSI) news
Greenwich Lifesciences, Inc. news releases on 6ix. Latest, Mar 2, 2021: Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C.…
Press releases — page 3
Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences
March 1, 2021
Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference
February 24, 2021
Greenwich LifeSciences CEO Interview to Air on Bloomberg International on the RedChip Money Report
January 28, 2021
Greenwich LifeSciences Announces Exercise and Closing of Underwriter’s Over-Allotment Option
January 28, 2021
Greenwich LifeSciences to Present at B. Riley Securities and BIO CEO & Investor Conferences
January 20, 2021
Greenwich LifeSciences to Participate in Multiple Virtual Investor Conferences During 2021 JP Morgan Healthcare Week
January 7, 2021
Greenwich LifeSciences’ LD Micro Presentation Replay Now Available
January 4, 2021
Greenwich LifeSciences to Ring Nasdaq Opening Bell on December 28
December 23, 2020
Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock
December 21, 2020
Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock
December 17, 2020
Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates
December 14, 2020
Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer
December 10, 2020
Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer
December 8, 2020
Greenwich LifeSciences Announces New Manufacturing Agreement for its Planned Phase III Clinical Trial and Enters into Lease for Office and Lab Space
December 2, 2020
Greenwich LifeSciences to Present at the Annual LD Micro Main Event
December 1, 2020
Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer
November 22, 2020
Greenwich LifeSciences Announces Publication of Positive Phase IIb Clinical Trial Data for GP2, Its Lead Drug Candidate for the Prevention of Recurring Breast Cancer
November 17, 2020
Greenwich LifeSciences, Inc. Announces Partnership with Baylor College of Medicine for its Planned Phase III Clinical Trial
November 11, 2020
Greenwich LifeSciences, Inc. Announces Acceptance of Two Abstracts at Upcoming Major Breast Cancer Conference
October 7, 2020
Greenwich LifeSciences, Inc. Announces Completion of Manufacturing of Drug for its Planned Phase III Clinical Trial
October 5, 2020
Greenwich LifeSciences, Inc. Announces Closing of Initial Public Offering
September 28, 2020
Greenwich LifeSciences, Inc. Announces Pricing of Initial Public Offering
September 23, 2020